Adjuvanticity of a recombinant calreticulin fragment in assisting anti-β-glucan igG responses in T cell-deficient mice

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 582-589

  Li, Wei Ji ^a   Long, Kai ^a   Dong, Hong Liang ^b   Gao, Xiao Ming ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIBODY; BETA GLUCAN ANTIBODY; CALRETICULIN; IMMUNOGLOBULIN G; LAMINARAN; LAMINARIN CALRETICULIN; RECOMBINANT CALRETICULIN; UNCLASSIFIED DRUG;

ADJUVANTICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENCY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, FUNGAL; CALRETICULIN; CANDIDA ALBICANS; CANDIDIASIS; FEMALE; FUNGAL VACCINES; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, NUDE; POLYSACCHARIDES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84876495700     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00689-12     Document Type: Article

References (41)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
2. Moyes DL, Naglik Jr. 2011. Mucosal immunity and Candida albicans infection. Clin. Dev. Immunol. 2011:346307. doi:10.1155/2011/346307.
3. Xin H, Dziadek S, Bundle DR, Cutler JE. 2008. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. U. S. A. 105:13526-13531.
4. Han Y, Cutler JE. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
5. Cutler JE. 2005. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5:383-392.
6. Bromuro C, Romano M, Chiani P, Berti F, Tontini M, Proietti D, Mori E, Torosantucci A, Costantino P, Rappuoli R, Cassone A. 2010. Betaglucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28:2615-2623.
7. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, Costantino P, Mosci P, d'Enfert C, Rappuoli R, Cassone A, Vecchiarelli A. 2010. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28:1717-1725.
8. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606.
9. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, Zamboni S, Feizi T, Cassone A. 2009. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 4:e5392. doi:10.1371/journal.pone .0005392.
10. Coutinho A, Moller G. 1973. Mitogenic properties of the thymusindependent antigen pneumococcal polysaccharide S3. Eur. J. Immunol. 3:608-613.
11. Beuvery EC, van Rossum F, Nagel J. 1982. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37:15-22.
12. Ragupathi G, Koganty RR, Qiu D, Lloyd KO, Livingston PO. 1998. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: Synthesis of sialyl Tn-KLH conjugate using a 4-(4-Nmaleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj. J. 15:217-221.
13. Mochon AB, Cutler JE. 2005. Is a vaccine needed against Candida albicans? Med. Mycol. 43:97-115.
14. Deepe GS, Jr. 2004. Preventative and therapeutic vaccines for fungal infections: From concept to implementation. Expert Rev. Vaccines 3:701-709.
15. Pollard AJ, Perrett KP, Beverley PC. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9:213-220.
16. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:277-296.
17. Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE. 2012. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 7:e35106. doi:10.1371/journal.pone.0035106.
18. Arosa FA, de Jesus O, Porto G, Carmo AM, de Sousa M. 1999. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. J. Biol. Chem. 274:16917-16922.
19. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. 1999. Calreticulin: One protein, one gene, many functions. Biochem. J. 344(Pt 2):281-292.
20. Vassilakos A, Michalak M, Lehrman MA, Williams DB. 1998. Oligosaccharide binding characteristics of the molecular chaperones calnexin and calreticulin. Biochemistry 37:3480-3490.
21. Pockley AG. 2003. Heat shock proteins as regulators of the immune response. Lancet 362:469-476.
22. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. 2002. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23:130-135.
23. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, Michalak M, Murphy-Ullrich JE. 2010. Calreticulin: Nonendoplasmic reticulum functions in physiology and disease. FASEB J. 24: 665-683.
24. Hong C, Qiu X, Li Y, Huang Q, Zhong Z, Zhang Y, Liu X, Sun L, Lv P, Gao XM. 2010. Functional analysis of recombinant calreticulin fragment 39-272: Implications for immunobiological activities of calreticulin in health and disease. J. Immunol. 185:4561-4569.
25. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. 2001. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108: 669-678.
26. Park YS, Lee JH, Hung CF, Wu TC, Kim TW. 2008. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 76: 1952-1959.
27. Qiu X, Hong C, Li Y, Bao W, Gao XM. 2012. Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus. Microbiol. Immunol. 56:554-561.
28. Read SM, Currie G, Bacic A. 1996. Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry. Carbohydr. Res. 281:187-201.
29. Bromuro C, Torosantucci A, Chiani P, Conti S, Polonelli L, Cassone A. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462-5470.
30. Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. 1990. Immunogenicity in animals of a polysaccharideprotein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1428-1433.
31. Wortis HH. 1974. Immunological studies of nude mice. Contemp. Top. Immunobiol. 3:243-263.
32. Qiu X, Hong C, Zhong Z, Li Y, Zhang T, Bao W, Xiong S, Gao XM. 2012. Modulation of cellular immunity by antibodies against calreticulin. Eur. J. Immunol. 42:2419-2430.
33. Ge FF, Qiu YF, Yang YW, Chen PY. 2007. An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus. Arch. Virol. 152:125-135.
34. Hu T, Li D, Zhao Y. 2009. Development of the hsp110-heparanase vaccine to enhance antitumor immunity using the chaperoning properties of hsp110. Mol. Immunol. 47:298-301.
35. Basu S, Binder RJ, Ramalingam T, Srivastava PK. 2001. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313.
36. Ghiran I, Klickstein LB, Nicholson-Weller A. 2003. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J. Biol. Chem. 278:21024-21031.
37. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV. 2004. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J. Biol. Chem. 279:51250-51257.
38. Brown GD, Gordon S. 2003. Fungal beta-glucans and mammalian immunity. Immunity 19:311-315.
39. Kavishwar A, Shukla PK. 2006. Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans. Med. Mycol. 44:159-167.
40. Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, Polonelli L, Ponton J. 2003. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71:5273-5279.
41. Cassone A, Torosantucci A. 2006. Opportunistic fungi and fungal infections: The challenge of a single, general antifungal vaccine. Expert Rev. Vaccines 5:859-867.